The regional pharmacovigilance centre in Caen, France has studied the adverse effects of drugs used to treat patients suffering from Alzheimer’s disease.
According to the study, carried out in north-west France, a third of the adverse effects reported were cardiovascular disorders and another third were neurological disorders. 62% of the adverse effects (out of 71) were serious. 2 patients continued to suffer after-effects and 3 died, 2 as a result of the adverse effect (aggravation of a bronchial spasm and serous cardiac arrhythmia).
In 21% of cases, the adverse effect appeared shortly after treatment commenced or after an increase in the dosage.
The data confirms other findings already published: the benefit of these treatments is often too limited to run the risk of such serious adverse effects.
©Prescrire November 2007
Source:
"Anti-Alzheimer : des effets indésirables graves souvent mortels (suite)" Rev Prescrire 2007 ; 27 (289) : 828
- More articles in Prescrire's "Spotlight"...